| Outcome Measures: |
Primary: Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+)., Baseline and Final Visit. | Secondary: Change from Baseline in Circulating Progenitor Cells Integrated Markers of cardiovascular risk (CD34+)., Baseline and Weeks 12 and 24.|Change from Baseline in Flow Mediated Dilation Integrated Markers of cardiovascular risk., Baseline and Final Visit.|Modulation of Endothelial Progenitor Cell recruitment (vascular endothelial growth factor, erythropoietin and stromal cell-derived factor-1)., Weeks: 4, 12 and 24.|Measure of Glucose Control (glycosylated hemoglobin and fasting plasma glucose)., Weeks: 4, 12 and 24.|Measure of Lipid Parameters (total lipids, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein B and apolipoprotein A1)., Weeks: 4, 12 and 24.|Change from Baseline in lipid parameters (free fatty acids and oxidized low-density lipoprotein)., Baseline and Weeks 12 and 24.|Change from Baseline in insulin sensitivity (insulin indexes by 2 hour oral glucose tolerance test with glucose, insulin and C-peptide estimation)., Baseline and Final Visit.|Change from Baseline in Inflammation Markers (high-sensitivity C-reactive protein, IL-6, vascular adhesion molecules (E-selectin, vascular cell adhesion molecule-1), monocyte chemotactic protein-1 and tumor necrosis factor-alpha)., Baseline and Weeks 12 and 24.|Change from Baseline in Adipokines (adiponectin)., Baseline and Weeks 12 and 24.|Change from Baseline in Oxidative Stress (maleic dialdehyde, ferric reducing antioxidant power and lipid hydroperoxide., Baseline and Weeks 12 and 24.|Urinary albumin excretion., Weeks: 12 and 24.
|
